HUP0300566A2 - Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában - Google Patents

Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában

Info

Publication number
HUP0300566A2
HUP0300566A2 HU0300566A HUP0300566A HUP0300566A2 HU P0300566 A2 HUP0300566 A2 HU P0300566A2 HU 0300566 A HU0300566 A HU 0300566A HU P0300566 A HUP0300566 A HU P0300566A HU P0300566 A2 HUP0300566 A2 HU P0300566A2
Authority
HU
Hungary
Prior art keywords
alzheimer
disease
galantamine
neuropsychiatric
treatment
Prior art date
Application number
HU0300566A
Other languages
English (en)
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HUP0300566A2 publication Critical patent/HUP0300566A2/hu
Publication of HUP0300566A3 publication Critical patent/HUP0300566A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A galantamint számos krónikus betegség gyógyításában alkalmazzák. Agalantamin hatásosan és biztonsággal alkalmazható az Alzheimer-kórterápiájában is. Az Alzheimer-kór általában együtt járneuropszichiátriai rendellenességekkel. Jelen találmánybanbebizonyítják, hogy a galantamin hatékonyan alkalmazható az Alzheimer-kóros betegeknél a neuropszichiátriai viselkedésformák előfordulásigyakoriságának csökkentésében vagy a neuropszichiátriai státuszstabilizálásában. Ó
HU0300566A 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease HUP0300566A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Publications (2)

Publication Number Publication Date
HUP0300566A2 true HUP0300566A2 (hu) 2003-06-28
HUP0300566A3 HUP0300566A3 (en) 2004-10-28

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300566A HUP0300566A3 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Country Status (20)

Country Link
EP (1) EP1272192A2 (hu)
JP (1) JP2003528913A (hu)
KR (1) KR20020086911A (hu)
CN (1) CN1430514A (hu)
AU (2) AU2001265844B2 (hu)
BG (1) BG107093A (hu)
BR (1) BR0109770A (hu)
CA (1) CA2310926C (hu)
CZ (1) CZ20023543A3 (hu)
EE (1) EE200200554A (hu)
HR (1) HRP20020778A2 (hu)
HU (1) HUP0300566A3 (hu)
IL (1) IL152061A0 (hu)
MX (1) MXPA02009777A (hu)
NO (1) NO20024746L (hu)
PL (1) PL361272A1 (hu)
RU (1) RU2002129298A (hu)
SK (1) SK15422002A3 (hu)
WO (1) WO2001074339A2 (hu)
ZA (1) ZA200207935B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
EP1651234B1 (en) 2003-07-25 2007-09-26 F. Hoffmann-La Roche Ag Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
PL2271218T3 (pl) 2008-03-27 2017-10-31 Chase Pharmaceuticals Corp Zastosowanie i kompozycja do leczenie otępienia
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
US20180200259A1 (en) * 2015-05-18 2018-07-19 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOID ß
CN117957003A (zh) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
EP1133230A4 (en) 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
DE69912311T2 (de) * 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
CA2310926C (en) 2002-10-15
HUP0300566A3 (en) 2004-10-28
MXPA02009777A (es) 2003-03-27
BG107093A (bg) 2003-06-30
EP1272192A2 (en) 2003-01-08
WO2001074339A2 (en) 2001-10-11
WO2001074339A3 (en) 2002-09-12
NO20024746L (no) 2002-11-28
PL361272A1 (en) 2004-10-04
AU2001265844B2 (en) 2005-04-14
SK15422002A3 (sk) 2003-04-01
CZ20023543A3 (cs) 2003-03-12
RU2002129298A (ru) 2004-03-27
AU6584401A (en) 2001-10-15
JP2003528913A (ja) 2003-09-30
IL152061A0 (en) 2003-05-29
KR20020086911A (ko) 2002-11-20
BR0109770A (pt) 2003-02-04
NO20024746D0 (no) 2002-10-02
ZA200207935B (en) 2004-01-30
HRP20020778A2 (en) 2004-04-30
CN1430514A (zh) 2003-07-16
CA2310926A1 (en) 2000-10-04
EE200200554A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
TW200509968A (en) Prevention and treatment of synucleinopathic disease
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
HUP0300426A2 (hu) Antihipertenzív és anti-angiogén szerek terápiás kombinációja és ezeket tartalmazó gyógyszerkészítmények
GB0223040D0 (en) Therapeutic compounds
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
BG105575A (en) Method and agent for the treatment of cerebral ischaemia
DK1296671T3 (da) Gabapentinanaloger til sövnforstyrrelser
DE69830512D1 (de) Heilmittel für neurodegenerative krankheiten
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
MY135838A (en) Methods for the treatment of mental disorders
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
HUP0300566A2 (hu) Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
GB0020504D0 (en) Therapeutic method
ATE310517T1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
HUP0204048A2 (hu) Dezloratadin alkalmazása allergiás és gyulladásos tünetek kezelésére
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
IL147188A (en) Use of il6ril6 chimera in the manufacture of a remedy for neurological diseases
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees